Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cansortium in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.09.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Cansortium. This rating has held steady since October 2023, when it changed from a Buy consensus rating.
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. The company's medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, and edibles under the Fluent brand name. It also sells various third-party branded medical cannabis products. The company was incorporated in 2018 and is headquartered in Miami, Florida.
Read More